

DAFTAR PUSTAKA

- Andi S.S., 2005. Penilaian Keseimbangan dengan Aktivitas Kehidupan Sehari-hari pada Lansia Di Panti Wredha Pelkris Elim Semarang Dengan Menggunakan Berg Balance Scale Dan Indeks Barthel. Program Studi Rehabilitasi Medik Fakultas Kedokteran Universitas Diponegoro Semarang.
- Amelot, A., De Cremoux, P., Quillien, V., Polivka, M., Adle-Biassette, H., Lehmann-Che, J., Françoise, L., Carpentier, A.F., George, B., Mandonnet, E. and Froelich, S., 2015. IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. *PLoS One*, 10(7), p.e0130596.
- Bennett, M. and Ryall, N., 2000. Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study. *Bmj*, 321(7273), pp.1381-1382.
- Bleeker, F.E., Atai, N.A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K.S., Tigchelaar, W., Troost, D., Vandertop, W.P., Bardelli, A. and Van Noorden, C.J., 2010. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. *Acta neuropathologica*, 119(4), pp.487-494.
- Brazil, L., Thomas, R., Laing, R., Hines, F., Guerrero, D., Ashley, S. and Brada, M., 1997. Verbally administered Barthel Index as functional assessment in brain tumour patients. *Journal of neuro-oncology*, 34(2), pp.187-192.
- Collin, C., Wade, D.T., Davies, S. and Horne, V., 1988. The Barthel ADL Index: a reliability study. *International disability studies*, 10(2), pp.61-63.
- Fisher, J.L., Schwartzbaum, J.A., Wrensch, M. and Wiemels, J.L., 2007. Epidemiology of brain tumors. *Neurologic clinics*, 25(4), pp.867-890.
- Goodenberger, M.L. and Jenkins, R.B., 2012. Genetics of adult glioma. *Cancer genetics*, 205(12), pp.613-621.
- Grier, J.T. and Batchelor, T., 2006. Low-grade gliomas in adults. *The Oncologist*, 11(6), pp.681-693.
- Guo, C., Pirozzi, C.J., Lopez, G.Y. and Yan, H., 2011. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. *Current opinion in neurology*, 24(6), p.648.

- Gupta, R., Webb-Myers, R., Flanagan, S. and Buckland, M.E., 2011. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. *Journal of clinical pathology*, pp.jclinpath-2011.
- Hartmann, C., Meyer, J., Bals, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W. and Weller, M., 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta neuropathologica*, 118(4), pp.469-474.
- Jessen, K.R. and Mirsky, R., 1980. Glial cells in the enteric nervous system contain glial fibrillary acidic protein. *Nature*, 286(5774), pp.736-737.
- Kim, S.I., Lee, Y., Won, J.K., Park, C.K., Choi, S.H. and Park, S.H., 2017. Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. *Journal of pathology and translational medicine*.
- Kementrian Kesehatan Republik Indonesia, 2015. Pedoman Nasional Pelayanan Kedokteran Tumor Otak. Komite Penanggulangan Kanker Nasional.
- Lee, S.M., Koh, H.J., Park, D.C., Song, B.J., Huh, T.L. and Park, J.W., 2002. Cytosolic NADP⁺-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. *Free Radical Biology and Medicine*, 32(11), pp.1185-1196.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvett, A., Scheithauer, B.W. and Kleihues, P., 2007. The 2007 WHO classification of tumours of the central nervous system. *Acta neuropathologica*, 114(2), pp.97-109.
- Mahoney, F.I. and Barthel, D.W., 1965. Functional evaluation: the Barthel Index: a simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. *Maryland state medical journal*.
- Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K. and Saito, N., 2012. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. *Cancer science*, 103(3), pp.587-592.
- Munshi, A. and Jalali, R., 2009. Therapy for glioma: Indian perspective. *Indian journal of cancer*, 46(2), p.127.

- Ohgaki, H. and Kleihues, P., 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. *Journal of Neuropathology & Experimental Neurology*, 64(6), pp.479-489.
- Ostrom, Q.T., Bauchet, L., Davis, F.G., Deltour, I., Fisher, J.L., Langer, C.E., Pekmezci, M., Schwartzbaum, J.A., Turner, M.C., Walsh, K.M. and Wrensch, M.R., 2014. The epidemiology of glioma in adults: a “state of the science” review. *Neuro-oncology*, 16(7), pp.896-913.
- Padmosantjojo RM. Brain Tumors in Indonesia. Proceedings of the 17th Asia Pasific Cancer Congress; 2003; Bali, Indonesia
- Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., Gallia, G.L. and Olivi, A., 2008. An integrated genomic analysis of human glioblastoma multiforme. *Science*, 321(5897), pp.1807-1812.
- Posti, J.P., Bori, M., Kauko, T., Sankinen, M., Nordberg, J., Rahi, M., Frantzen, J., Vuorinen, V. and Sipilä, J.O.T., 2015. Presenting symptoms of glioma in adults. *Acta Neurologica Scandinavica*, 131(2), pp.88-93.
- Prensner, J.R. and Chinnaiyan, A.M., 2011. Metabolism unhinged: IDH mutations in cancer. *Nature medicine*, 17(3), pp.291-293.
- Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K. and Delattre, J.Y., 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. *Journal of clinical oncology*, 27(25), pp.4150-4154.
- Schwartzbaum, J.A., Fisher, J.L., Aldape, K.D. and Wrensch, M., 2006. Epidemiology and molecular pathology of glioma. *Nature clinical practice Neurology*, 2(9), pp.494-503.
- Sonoda, Y., Kumabe, T., Nakamura, T., Saito, R., Kanamori, M., Yamashita, Y., Suzuki, H. and Tominaga, T., 2009. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. *Cancer science*, 100(10), pp.1996-1998.
- Thomas, R., James, N., Guerrero, D., Ashley, S., Gregor, A. and Brada, M., 1994. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. *Radiotherapy and Oncology*, 33(2), pp.113-116.
- Ward, P.S., 2013. The common feature of cancer-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α -ketoglutarate to the

oncometabolite 2-hydroxyglutarate (Doctoral dissertation, University of Pennsylvania).

Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J. and Friedman, H., 2009. IDH1 and IDH2 mutations in gliomas. *New England Journal of Medicine*, 360(8), pp.765-773.

Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y. and Ding, J., 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α . *Science*, 324(5924), pp.261-265.